[A16-25] Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V
|2016-08-01||Dossier assessment (German version)||2 MB|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2016-10-20 A G-BA decision was published.